TNKase (T-N-Kase, tenecteplase), a new thrombolytic for treating heart attacks

July 2000

You'll hear about TNKase (T-N-Kase, tenecteplase), a new thrombolytic for treating heart attacks.

Hoffmann LaRoche has introduced it in the U.S. It's being considered in Canada.

TNKase is a modified version of Activase (alteplase, tPA). It's made by substituting 3 amino acids of the tPA enzyme.

Practical advice for a better career, with unlimited access to CE

Pharmacy Technician's Letter Canada includes:

12 issues every year, with brief articles about new meds and hot topics
120+ CE courses, including the popular CE-in-the-Letter
Helpful, in-depth Technician Tutorials
Access to the entire archive

Subscribe Today!

Already a subscriber? Log in

Volume pricing available. Get a quote

Table of Contents

new guidelines for treating asthma during pregnancy
Qvar, the first CFC-free beclomethasone dipropionate inhaler for asthma
Women's Health lengthening oral contraceptive cycles
Women's Health taking low-dose oral contraceptives right up until menopause
Stroke most patients should get ASA for an acute ischemic stroke
Allergic Reactions which drugs might cause problems in patients with sulfa allergies
Gastroenterology taking Prepulsid (cisapride) off the market
Gastroenterology Cynara-SL, a new dietary supplement made from artichokes
Renagel, a new drug to lower serum phosphorus in patients with end-stage renal disease
Men's Health PC-SPES (pea-see spehz) for prostate cancer
Men's Health Gonal-F for treating infertility in MEN
Breast Cancer Arimidex (anastrozole) is now approved as first-line therapy of advanced breast cancer
Cardiology more aggressive treatment of SYSTOLIC hypertension
Cardiology TNKase (T-N-Kase, tenecteplase), a new thrombolytic for treating heart attacks
Cholesterol start statins EARLIER after a heart attack
Practice splendid review of our Natural Medicines Comprehensive Database
Infectious Diseases new guidelines for treating latent tuberculosis